Product Description

Kixta 125mg Capsule contains palbociclib, a highly selective cyclin-dependent kinase (CDK) 4 and 6 inhibitor used in the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. Palbociclib targets and blocks the activity of CDK4 and CDK6 proteins, which play a crucial role in driving cancer cell division. By interfering with this process, Kixta helps slow down the progression of the disease and enhances the effectiveness of hormone therapy. It is typically prescribed alongside endocrine treatments like letrozole or fulvestrant and is taken in a 28-day regimen consisting of 21 days on treatment followed by 7 days off. This makes Kixta a convenient, once-daily oral option for long-term cancer management.